CN115645388B - 氨基酸组合物及其用途 - Google Patents

氨基酸组合物及其用途 Download PDF

Info

Publication number
CN115645388B
CN115645388B CN202211258479.XA CN202211258479A CN115645388B CN 115645388 B CN115645388 B CN 115645388B CN 202211258479 A CN202211258479 A CN 202211258479A CN 115645388 B CN115645388 B CN 115645388B
Authority
CN
China
Prior art keywords
cells
composition
therapeutically effective
ors
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202211258479.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN115645388A (zh
Inventor
S·维德亚瑟格
R·古普塔
L·尹
A·格罗舍
P·G·奥库尼夫
S·加托
D·丹尼森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amy Leif LLC
University of Florida Research Foundation Inc
Original Assignee
Entelinco LLC
University of Florida Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entelinco LLC, University of Florida Research Foundation Inc filed Critical Entelinco LLC
Publication of CN115645388A publication Critical patent/CN115645388A/zh
Application granted granted Critical
Publication of CN115645388B publication Critical patent/CN115645388B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202211258479.XA 2016-10-04 2017-10-04 氨基酸组合物及其用途 Active CN115645388B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662403965P 2016-10-04 2016-10-04
US62/403,965 2016-10-04
US201662421443P 2016-11-14 2016-11-14
US62/421,443 2016-11-14
CN201780074351.9A CN110062621B (zh) 2016-10-04 2017-10-04 氨基酸组合物及其用途
PCT/US2017/055167 WO2018067717A1 (en) 2016-10-04 2017-10-04 Amino acid compositions and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780074351.9A Division CN110062621B (zh) 2016-10-04 2017-10-04 氨基酸组合物及其用途

Publications (2)

Publication Number Publication Date
CN115645388A CN115645388A (zh) 2023-01-31
CN115645388B true CN115645388B (zh) 2024-12-10

Family

ID=61831937

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202211258479.XA Active CN115645388B (zh) 2016-10-04 2017-10-04 氨基酸组合物及其用途
CN201780074351.9A Active CN110062621B (zh) 2016-10-04 2017-10-04 氨基酸组合物及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780074351.9A Active CN110062621B (zh) 2016-10-04 2017-10-04 氨基酸组合物及其用途

Country Status (9)

Country Link
US (1) US11576884B2 (https=)
EP (1) EP3522882A4 (https=)
JP (2) JP7267546B2 (https=)
CN (2) CN115645388B (https=)
AU (1) AU2017338887B2 (https=)
BR (1) BR112019006742A2 (https=)
CA (2) CA3135553C (https=)
MX (1) MX2019003821A (https=)
WO (1) WO2018067717A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX350541B (es) 2010-09-24 2017-09-08 Univ Florida Materiales y metodos para mejorar la funcion gastrointestinal.
EP2968241B1 (en) 2013-03-11 2018-10-31 University of Florida Research Foundation, Inc. Materials and methods for improving lung function and for prevention and/or treatment of radiation-induced lung complications
US20230255916A1 (en) * 2016-10-04 2023-08-17 University Of Florida Research Foundation, Inc. Amino acid compositions and uses thereof
JP2021520351A (ja) * 2018-04-04 2021-08-19 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 皮膚を治療するための組成物
WO2020028129A1 (en) * 2018-07-30 2020-02-06 Almeda Labs Llc Cardioprotective amino acid formulations
RU2709502C1 (ru) * 2019-09-23 2019-12-18 Виктор Александрович Сисев Фармацевтическая композиция для парентерального капельного введения
EP4084784A4 (en) * 2020-01-13 2024-01-17 Monash University Compositions and methods
JP7470376B2 (ja) * 2020-03-31 2024-04-18 国立大学法人山口大学 顎下腺の萎縮抑制剤及び創傷治癒促進剤
IL299488A (en) * 2020-07-02 2023-02-01 Univ Florida Preparations for promoting hydration and methods of using them
CN114097952A (zh) * 2020-08-28 2022-03-01 河北科星药业有限公司 毛丝鼠专用的营养添加剂、其制备方法及应用
EP4460290A4 (en) * 2022-01-03 2025-08-13 Entrinsic Llc SKIN CARE FORMULATIONS AND METHODS
US11878073B1 (en) 2022-09-20 2024-01-23 Entrinsic, LLC Generation of hydration-targeted formulations and methods of use therein
CN117085142A (zh) * 2023-08-04 2023-11-21 中山大学附属第七医院(深圳) 一种负载小分子药物的间充质干细胞外泌体及其制备方法与应用
CN117159520B (zh) * 2023-08-17 2026-04-07 中国人民解放军海军军医大学第一附属医院 竹红菌甲素在制备抑制胰腺纤维化的药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105120856A (zh) * 2013-03-11 2015-12-02 佛罗里达大学研究基金会有限公司 用于改善肺功能和用于预防和/或治疗辐射诱发的肺并发症的材料和方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6130394A (en) 1991-03-05 1994-08-15 Miris Medical Corporation Apparatus for providing a timed release of an amount of aerosol medication
DE69230613T2 (de) 1991-07-02 2000-12-28 Inhale Inc Verfahren und vorrichtung zum abgeben von medikamenten in aerosolform
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US5558085A (en) 1993-01-29 1996-09-24 Aradigm Corporation Intrapulmonary delivery of peptide drugs
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
HUP9800049A3 (en) 1995-02-23 1999-01-28 Novartis Nutrition Ag Amino acid compositions and use thereof in clinical nutrition, and use of the said amino acids for preparing pharmaceutical compns. for the diminution of tnf
AU5719798A (en) 1996-12-31 1998-07-31 Inhale Therapeutic Systems, Inc. Processes for spray drying aqueous suspensions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes
MXPA01002875A (es) 1998-11-13 2002-04-08 Los Angeles Childrens Hospital Metodos para facilitar el crecimiento vascular.
GB0009056D0 (en) 2000-04-12 2000-05-31 Nestle Sa Composition comprising free amino acids
CA2557814A1 (en) 2004-03-01 2005-09-15 Lumen Therapeutics, Llc Compositions and methods for treating diseases
US20070010459A1 (en) 2005-01-14 2007-01-11 Ying Liu Application of asiatic acid and its derivatives to treat pulmonary fibrosis
EP1864692A1 (en) 2006-06-07 2007-12-12 Biotempt B.V. Use of peptides for the control of radiation injury
ES2525223T3 (es) * 2006-08-04 2014-12-19 Shs International Ltd. Fórmula sin proteínas
CN101815441A (zh) * 2007-08-03 2010-08-25 安敏诺技术公司 氨基酸和肽产品
JP5576097B2 (ja) * 2009-11-17 2014-08-20 大塚製薬株式会社 気道抵抗改善剤
IT1396935B1 (it) 2009-11-26 2012-12-20 Solartium Entpr Ltd Uso di una combinazione per il trattamento delle mucositi indotte da radiazioni o da chemioterapici
IT1397023B1 (it) * 2009-11-27 2012-12-20 Professional Dietetics Srl Composizioni comprendenti amminoacidi, per il trattamento della broncopneumopatia cronica ostruttiva
AU2011203862A1 (en) * 2010-01-08 2012-07-26 President And Fellows Of Harvard College D- amino acids for use in treating biofilms
MX350541B (es) 2010-09-24 2017-09-08 Univ Florida Materiales y metodos para mejorar la funcion gastrointestinal.
JP2012214451A (ja) * 2011-03-25 2012-11-08 En Otsuka Pharmaceutical Co Ltd 炎症性疾患用アミノ酸組成物
WO2013093947A1 (en) * 2011-12-21 2013-06-27 Motolese Pasquale Cosmetic composition and uses thereof in the treatment of lipodystrophies
HK1204290A1 (en) 2012-02-08 2015-11-13 University Of Florida Research Foundation, Inc. Materials and methods for treating diarrhea
DE102013224993A1 (de) * 2013-12-05 2015-06-11 Henkel Ag & Co. Kgaa Haarbehandlungsmittel mit substituierten Silikon(en)
US10413528B2 (en) * 2014-10-20 2019-09-17 John H. Plumb Methods to inhibit infection during wound healing with topical compositions including amino acids
MX2017006748A (es) * 2014-11-24 2017-08-28 Entrinsic Health Solutions Inc Composiciones de aminoácidos para el tratamiento de síntomas de enfermedades.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105120856A (zh) * 2013-03-11 2015-12-02 佛罗里达大学研究基金会有限公司 用于改善肺功能和用于预防和/或治疗辐射诱发的肺并发症的材料和方法

Also Published As

Publication number Publication date
JP7593577B2 (ja) 2024-12-03
CA3039514A1 (en) 2018-04-12
AU2017338887B2 (en) 2020-09-03
JP7267546B2 (ja) 2023-05-02
JP2023100617A (ja) 2023-07-19
CN115645388A (zh) 2023-01-31
WO2018067717A1 (en) 2018-04-12
CA3135553A1 (en) 2018-04-12
CN110062621A (zh) 2019-07-26
CA3135553C (en) 2024-05-21
BR112019006742A2 (pt) 2019-09-03
MX2019003821A (es) 2019-12-18
JP2019530750A (ja) 2019-10-24
CA3039514C (en) 2022-01-25
EP3522882A1 (en) 2019-08-14
EP3522882A4 (en) 2020-06-24
AU2017338887A1 (en) 2019-05-02
US11576884B2 (en) 2023-02-14
US20210283081A1 (en) 2021-09-16
CN110062621B (zh) 2022-11-01

Similar Documents

Publication Publication Date Title
CN115645388B (zh) 氨基酸组合物及其用途
US20190388369A1 (en) Use of N-acetylcysteine Amide in the Treatment Of Disease and Injury
AU2018203026A1 (en) Pharmaceutical compositions and methods
WO2016049867A1 (zh) 以外源性线粒体为有效成份的组合物、其用途及修复细胞的方法
Zhang et al. S-allylmercapto-N-acetylcysteine ameliorates pulmonary fibrosis in mice via Nrf2 pathway activation and NF-κB, TGF-β1/Smad2/3 pathway suppression
US20210145797A1 (en) Compositions for treating skin
US20170080093A1 (en) Tyrosine Derivatives And Compositions Comprising Them
JP2022153587A (ja) チロシン誘導体及びそれらを含む組成物
KR102666922B1 (ko) 미토콘드리아에 비오틴의 전달을 위한 방법 및 조성물
KR20220098144A (ko) 암을 치료하는 데에 사용하기 위한 알파-메틸-dl-티로신의 알킬에스테르
US20210145806A1 (en) Methods of Treating Brain Cancer and Related Diagnostic Methods
US20230255916A1 (en) Amino acid compositions and uses thereof
BR122024018467A2 (pt) Formulações de aminoácido e usos das mesmas
CZ307851B6 (cs) Léčebný přípravek k prevenci a léčení zánětlivých a degenerativních onemocnění
TWI722492B (zh) 含蓮蓬萃取物之組合物及其用於治療頭頸癌症之用途
Nimbalkar et al. L‐Carnitine Protects Against Cisplatin‐Induced Activation of Human Hepatic Stellate Cells via Inflammatory Cytokines and Nitrosative Stress

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: Florida, USA

Patentee after: University OF FLORIDA RESEARCH FOUNDATION, INC.

Country or region after: U.S.A.

Patentee after: Amy Leif, LLC

Address before: Florida, USA

Patentee before: University OF FLORIDA RESEARCH FOUNDATION, INC.

Country or region before: U.S.A.

Patentee before: Entelinco LLC